Drug Trial Radar · NCT06662786
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Oct 18, 2024
Primary completion
Dec 15, 2028
Study completion Jan 20, 2032
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Oct 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type (WT) unresectable or metastatic left-sided colorectal cancer.
Conditions
- Colorectal Neoplasms
Interventions
AmivantamabBiological
Amivantamab will be administered.
CetuximabBiological
Cetuximab will be administered.
5-fluorouracilDrug
5-fluorouracil will be administered as chemotherapy regimen.
Leucovorin calcium/LevoleucovorinDrug
Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
OxaliplatinDrug
Oxaliplatin will be administered as chemotherapy regimen.
Irinotecan HydrochlorideDrug
Irinotecan hydrochloride will be administered as chemotherapy regimen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to 4 years and 2 months
Locations
239 sites in 22 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona · Recruiting
St. Bernard's Medical Center
Jonesboro, Arkansas · Recruiting
Highlands Oncology Group
Springdale, Arkansas · Recruiting
CBCC Global Research
Bakersfield, California · Recruiting
Los Angeles Cancer Network
Glendale, California · Recruiting
Cancer and Blood Specialty Clinic
Los Alamitos, California · Recruiting
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
UCLA
Santa Monica, California · Recruiting
Providence Medical Foundation
Santa Rosa, California · Recruiting
Torrance Memorial Physicians Network
Torrance, California · Recruiting
Rocky Mountain Cancer Centers
Denver, Colorado · Recruiting
Yale University School Of Medicine
New Haven, Connecticut · Recruiting
Georgetown Univ Medical Center Lombardi Cancer Center
Washington D.C., District of Columbia · Recruiting
Florida Cancer Specialists South
Fort Myers, Florida · Recruiting
AdventHealth Medical Group Oncology and Hematology at Orlando
Orlando, Florida · Recruiting
Florida Cancer Specialists North Region
St. Petersburg, Florida · Recruiting
Florida Cancer Specialists East
West Palm Beach, Florida · Recruiting
Grady Memorial Hospital
Atlanta, Georgia · Recruiting
Winship Cancer Institute Emory University
Atlanta, Georgia · Recruiting
Illinois Cancer Specialists
Arlington Heights, Illinois · Recruiting
Illinois CancerCare
Peoria, Illinois · Recruiting
Fort Wayne Medical Oncology & Hematology
Fort Wayne, Indiana · Recruiting
University of Iowa Hospital
Iowa City, Iowa · Recruiting
Mission Cancer Blood
Waukee, Iowa · Recruiting
Cancer Center of Kansas
Wichita, Kansas · Recruiting
Ochsner Clinic Foundation
New Orleans, Louisiana · Recruiting
MedStar Franklin Square Medical Center
Baltimore, Maryland · Recruiting
Frederick Health Hospital - James M Stockman Cancer Institute
Frederick, Maryland · Recruiting
VA Ann Arbor Healthcare System
Ann Arbor, Michigan · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Henry Ford Hospital
Detroit, Michigan · Recruiting
Cancer And Hematology Centers of Western Michigan PC
Grand Rapids, Michigan · Recruiting
Hattiesburg Clinic
Hattiesburg, Mississippi · Recruiting
Washington University School Of Medicine
St Louis, Missouri · Recruiting
Nebraska Cancer Specialists Midwest Cancer Center
Omaha, Nebraska · Recruiting
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada · Recruiting
Astera Cancer Care
East Brunswick, New Jersey · Recruiting
Rutgers Cancer Institute
New Brunswick, New Jersey · Recruiting
University of New Mexico Cancer Center
Albuquerque, New Mexico · Recruiting
Perlmutter Cancer Center at NYU Long Island
Mineola, New York · Recruiting
Showing 40 of 239 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.